Johnson Matthey (LON:JMAT - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Jefferies Financial Group in a report released on Tuesday, MarketBeat.com reports. They currently have a GBX 1,800 ($22.84) price objective on the stock. Jefferies Financial Group's price target suggests a potential upside of 30.62% from the company's previous close.
Separately, Berenberg Bank lowered their target price on Johnson Matthey from GBX 1,650 ($20.93) to GBX 1,500 ($19.03) and set a "hold" rating for the company in a research report on Thursday, November 28th.
View Our Latest Analysis on Johnson Matthey
Johnson Matthey Price Performance
Shares of JMAT stock traded down GBX 19 ($0.24) during trading hours on Tuesday, hitting GBX 1,378 ($17.48). The stock had a trading volume of 2,719,798 shares, compared to its average volume of 949,586. The stock's 50-day moving average price is GBX 1,477.53 and its two-hundred day moving average price is GBX 1,574.53. Johnson Matthey has a one year low of GBX 1,318 ($16.72) and a one year high of GBX 1,917.07 ($24.32). The stock has a market capitalization of £2.40 billion, a price-to-earnings ratio of 2,375.86, a PEG ratio of 49,242.50 and a beta of 0.95. The company has a debt-to-equity ratio of 63.15, a current ratio of 1.45 and a quick ratio of 0.76.
Insider Activity
In other Johnson Matthey news, insider Liam Condon bought 21 shares of the business's stock in a transaction dated Wednesday, September 18th. The shares were purchased at an average price of GBX 1,598 ($20.27) per share, with a total value of £335.58 ($425.75). Also, insider Stephen Oxley purchased 24 shares of the firm's stock in a transaction that occurred on Wednesday, November 20th. The shares were acquired at an average cost of GBX 1,504 ($19.08) per share, with a total value of £360.96 ($457.95). In the last 90 days, insiders have purchased 7,479 shares of company stock valued at $10,057,890. 0.61% of the stock is currently owned by insiders.
About Johnson Matthey
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
See Also
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.